Jul 18, 2025
Psychedelic‑Assisted Therapy: The Promise of Psilocybin for Treatment‑Resistant Depression
After decades of stalled innovation in severe depression, psilocybin—the psychoactive compound in “magic mushrooms”—is generating renewed hope. In 2018, the FDA granted Breakthrough Therapy Designation to COMP360, Compass Pathways’ synthetic psilocybin formulation for treatment‑resistant depression (Compass Pathways). This status accelerates review and fosters close FDA‑industry collaboration.…
